A novel composite hydrogel based on chitosan and inorganic phosphate for local drug delivery of camptothecin nanocolloids

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 232-241

  Li, XingYi ^a   Kong, XiangYe ^a   Zhang, Juan ^a   Wang, YingJing ^a   Wang, YuJun ^a   Shi, Shuai ^a   Guo, Gang ^a   Luo, Feng ^a   Zhao, Xia ^a   Wei, YuQuan ^a   Qian, ZhiYong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Camptothecin; Chitosan hydrogel; Inorganic phosphate; Sustained release; Thermo sensitivity

Indexed keywords

CAMPTOTHECIN; CHITOSAN; DISODIUM HYDROGEN PHOSPHATE; NANOCOMPOSITE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; COLLOID; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STORAGE; FEMALE; GEL; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN;

EID: 78650048629     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22256     Document Type: Article

References (36)

1. Hatefi A, Amsden B. 2002. Camptothecin delivery methods. Pharm Res 19: 1389-1399.
2. Hsiang YH, Hertzberg R, Hecht S, Liu LF. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878.
3. Hsiang YH, Lihou MG, Liu LF. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082.
4. Lerchen HG, Baumgarten J, von dem Bruch K, Lehmann TE, Sperzel M, Kempka G, Fiebig HH. 2001. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 44: 4186-4195.
5. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER, Biovanella BC. 1993. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 5: 273-281.
6. Rothenberg ML, Kuhn JG, Burris HA. 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11: 2194-2204.
7. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. 1972. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56: 515-521.
8. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. 1972. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101.
9. Thomas CJ, Rahier NJ, Hecht SM. 2004. Camptothecin: Current perspectives. Bioorgan Med Chem 12: 1585-1604.
10. Yang LX, Pan X, Wang HJ. 2002. Novel camptothecin derivatives. Part 1: Oxyalkanoic acid esters of camptothecin and their in vitro and in vivo antitumor activity. Bioorg Med Chem Lett 12: 1241-1244.
11. Conover CD, Pendri A, Lee C, Gilbert CW, Shum KL, Greenwald RB. 1997. Camptothecin delivery systems: The antitumor activity of a camptothecin-20-0-polyethylene glycol ester transport form. Anticancer Res 17: 3361-3368.
12. Cao Z, Harris N, Kozielski A, Vardeman D, Stehlin JS, Giovanella B. 1998. Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem 41: 31-37.
13. Gao SQ, Lu ZR, Petri B, Kope ková P, Kope ek J. 2006. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1, 6-elimination spacer. J Control Release 110: 323-331.
14. Singer JW, Bhatt R, Tulinsky J, Buhler KR, Heasley E, Klein P, de Vries P. 2001. Water-soluble poly-(l-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 74: 243-247.
15. Emerich DF, Snodgrass P, Lafreniere D, Dean RL, Salzberg H, Marsh J, Perdomo B, Arastu M, Winn SR, Bartus RT. 2002. Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res 19: 1052-1060.
16. Shenderova A, Burke TG, Schwendeman SP. 1999. The acidic microclimate in poly (lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 16: 241-248.
17. Ertl B, Platzer P, Wirth M, Gabor F. 1999. Poly(D, L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J Control Release 61: 305-317.
18. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H. 1995. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 62: 605-609.
19. Storm PB, Moriarity JL, Tyler B, Burger PC, Brem H, Weingart J. 2002. Polymer delivery of camptothecin against 9L gliosarcoma: Release, distribution, and efficacy. J Neuro-Oncol 56: 209-217.
20. Berrada M, Serreqi A, Dabbarh F, Owusu A, Gupta A, Lehnert S. 2005. A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials 26: 2115-2120.
21. Nair LS, Starnes T, Ko JWK, Laurencin CT. 2007. Development of injectable thermogelling chitosan-Inorganic phosphate solutions for biomedical applications. Biomacromolecules 8: 3779-3785.
22. Li XY, Kong XY, Shi S, Zheng XL, Zhang J, Liu TT, Zhao X, Wei YQ, Qian ZY. 2010. Preparation of N-trimethyl chitosan-protein nanoparticles intended for vaccine delivery. J Nanosci Nanotechnol 10: 4850-4858.
23. Porstmann B, Jung K, Schmechta H, Evers U, Pergande M, Porstmann T, Kramm HJ, Krause H. 1989. Measurement of lysozyme in human body fluids: Comparison of various enzyme immunoassay techniques and their diagnostic application. Clin Biochem 22: 349-355.
24. Masuda T, Ueno Y, Kitabatake N. 2001. Sweetness and enzymatic activity of lysozyme. J Agric Food Chem 49: 4937-4941.
25. Agarwal A, Lvov Y, Sawant R, Torchilin V. 2008. Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology. J Control Release 128: 255-260.
26. Vårum KM, Myhr MM, Hjerde RJN, Smidsrød O. 1997. In vitro degradation rates of partially N-acetylated chitosans in human serum. Carbohyd Res 299: 99-101.
27. Nordtveit RJ, Vårum KM, Smidsrød O. 1996. Degradation of partially N-acetylated chitosans with hen egg white and human lysozyme. Carbohyd Res 29: 163-167.
28. Jayakumar R, Prabaharan M, Reis RL, Mano JF. 2005. Graft copolymerized chitosan-Present status and applications. Carbohyd Polym 62: 142-158.
29. Ilium L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15: 1326-1331.
30. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, Leroux JC, Atkinson BL, Binette F, Selmani A. 2000. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 21: 2155-2161.
31. Li XY, Zheng XL, Wei XW, Guo G, Gou ML, Gong CY, Wang XH, Dai M, Chen LJ, Wei YQ. 2009. A Novel Composite Drug Delivery System: Honokiol nanoparticles in thermosensitive hydrogel based on chitosan. J Nanosci Nanotechnol 9: 4586-4592.
32. Li XY, Kong XY, Wang XH, Zheng XL, Shi S, Guo G, Luo F, Zhao X, Wei YQ, Qian ZY. Thermo-gelation behavior studies of chitosan-inorganic phosphate solutions. Eur J Pharm Biopharm DOI: 10.1016/j.ejpb.2010.04.015.
33. Don TM, Hsu SC, Chiu WY. 2001. Structures and thermal properties of chitosan-modified poly (methyl methacrylate). J Polym Sci Pol Chem 39: 1646-1655.
34. Rodr guez MS, Albertengo LA, Agullo E. 2002. Emulsification capacity of chitosan. Carbohyd polym 48: 271-276.
35. Kim A, Park SJ, Lee JR. 1998. Stabilization of liquid crystal-in-water dispersion with polymer/surfactant mixture: Nematic curvilinear aligned phase composite film. J Colloid Interf Sci 197: 119-125.
36. Wu J, Su ZG, Ma GH. 2006. A thermo-and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate. Int J Pharm 315: 1-11.